AHPA Stock Forecast 2025-2026
Distance to AHPA Price Targets
AHPA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Avista II (AHPA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AHPA and similar high-potential opportunities.
Latest AHPA Stock Price Targets & Analyst Predictions
AHPA has shown a year-to-date change of -48.9% and a 1-year change of -61.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for AHPA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AHPA Analyst Ratings
AHPA Price Target Range
Latest AHPA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AHPA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Avista Public Acquisition Corp. II (AHPA) Competitors
The following stocks are similar to Avista II based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Avista Public Acquisition Corp. II (AHPA) Financial Data
Avista Public Acquisition Corp. II has a market capitalization of $41.17M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Avista Public Acquisition Corp. II (AHPA) Business Model
Avista Public Acquisition Corp. II (AHPA) Latest News & Analysis
No relevant financial information is provided in the news excerpt. Please provide more details for a meaningful summary.
The location indicates potential regional economic developments, market trends, or corporate activities that could impact local businesses and investment opportunities.
OmniAb's business combination has received approval from APAC shareholders, indicating progress in their strategic partnership.
The approval of OmniAb's business combination signals a potential increase in market share and growth opportunities, impacting stock valuation and investor confidence.
Ligand announced that Janssen received U.S. FDA approval for TECVAYLI™ (teclistamab), potentially impacting Ligand's market position and investor interest.
FDA approval of TECVAYLI™ boosts Ligand’s partnership value and revenue potential, positively impacting stock performance and investor sentiment in biotech.
Avista Public Acquisition Corp. II (NASDAQ: AHPA) will hold an extraordinary general meeting on October 24, 2022, to vote on the proposed business combination with OmniAb.
The upcoming vote on APAC's business combination with OmniAb could significantly impact share value and market perception, influencing investment decisions related to both companies.
Ligand Pharmaceuticals has announced the record date and details for the distribution of its OmniAb spin-off.
Ligand's spin-off of OmniAb may signal value creation and a strategic shift, potentially impacting stock performance and investor sentiment toward both entities.
Ligand Pharmaceuticals has announced its financial results for the second quarter of 2022. Further details on earnings were provided in the report.
Ligand's financial results indicate company performance and potential growth. Positive earnings can boost stock value, while poor results may lead to declines, affecting investment strategies.
Frequently Asked Questions About AHPA Stock
What is Avista Public Acquisition Corp. II's (AHPA) stock forecast for 2025?
Analyst forecasts for Avista Public Acquisition Corp. II (AHPA) are not currently available. The stock is trading at $1.79.
Is AHPA stock a good investment in 2025?
Analyst ratings for AHPA are not currently available. The stock is currently trading at $1.79. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AHPA stock?
Price predictions from Wall Street analysts for AHPA are not currently available. The stock is trading at $1.79.
What is Avista Public Acquisition Corp. II's business model?
N/A
What is the highest forecasted price for AHPA Avista Public Acquisition Corp. II?
Price targets from Wall Street analysts for AHPA are not currently available. The stock is trading at $1.79.
What is the lowest forecasted price for AHPA Avista Public Acquisition Corp. II?
Price targets from Wall Street analysts for AHPA are not currently available. The stock is trading at $1.79.
What is the overall AHPA consensus from analysts for Avista Public Acquisition Corp. II?
Analyst ratings for AHPA are not currently available. The stock is trading at $1.79.
How accurate are AHPA stock price projections?
Stock price projections, including those for Avista Public Acquisition Corp. II, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.